Related Experiment Video
Updated: Sep 8, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic Challenges
Yi Da1, Giap Hean Goh2, Titus Lau1
1Division of Nephrology, Department of Medicine, National University Hospital, Singapore, Singapore.
Abstract:
Fibrillary glomerulonephritis (FGN) is a rare glomerular disease featured by the randomly arranged 12- to 24-nm fibrils under electron microscopy (EM). Up to 10% of FGN patients have monoclonal gammopathy. However, distinguishing between FGN as monoclonal gammopathy of renal significance (MGRS) and FGN from other causes with incidental monoclonal gammopathy of undetermined significance (MGUS) can be challenging, as the current way of demonstrating monoclonality is flawed due to (1) the suboptimal sensitivity of kappa staining by immunofluorescence in frozen tissue (IF-F) as compared to pronase-digested paraffin sections (IF-P), causing incorrect labeling of light chain restriction; (2) the unavailability of immunoglobulin G (IgG) subtyping in some centers; and (3) the unavailability of tests demonstrating the monoclonality of highly variable VH or VL domains in immunoglobulin structures in clinical use. The discovery of DnaJ homolog subfamily B member 9 (DNAJB9) allows diagnosis for FGN with less reliance on EM, and the summary of recent studies revealed that genuine MGRS is extremely rare among FGN. Further research integrating IF-P, IgG subtyping, VH or VL domain monoclonality confirmation, and DNAJB9 as diagnostic modalities, with corresponding clinical data including treatment response and prognosis, is required for a better understanding of this subject.
Insights
Distinguishing fibrillary glomerulonephritis (FGN) with monoclonal gammopathy of renal significance (MGRS) from incidental monoclonal gammopathy of undetermined significance (MGUS) is challenging. Recent findings suggest MGRS is rare in FGN, necessitating advanced diagnostic approaches.
Area of Science:
- Nephrology
- Pathology
- Immunology
Background:
- Fibrillary glomerulonephritis (FGN) is a rare kidney disease characterized by abnormal fibrils.
- Monoclonal gammopathy is present in up to 10% of FGN patients, complicating diagnosis.
- Current methods for demonstrating monoclonality in FGN are limited by sensitivity and availability.
Purpose of the Study:
- To address the diagnostic challenges in differentiating FGN with monoclonal gammopathy of renal significance (MGRS) from FGN with incidental monoclonal gammopathy of undetermined significance (MGUS).
- To highlight the limitations of current diagnostic techniques for assessing monoclonality in FGN.
- To emphasize the rarity of MGRS in FGN based on recent studies.
Main Methods:
- Review of current diagnostic limitations including immunofluorescence in frozen tissue (IF-F) vs. paraffin sections (IF-P), immunoglobulin G (IgG) subtyping, and VH/VL domain monoclonality tests.
- Consideration of DnaJ homolog subfamily B member 9 (DNAJB9) as a diagnostic marker for FGN.
- Analysis of recent studies summarizing the incidence of MGRS in FGN.
Main Results:
- Current kappa staining by immunofluorescence in frozen tissue (IF-F) shows suboptimal sensitivity compared to pronase-digested paraffin sections (IF-P).
- Limitations exist in the availability of IgG subtyping and tests for VH/VL domain monoclonality in clinical settings.
- Recent research indicates that genuine MGRS is extremely rare among FGN patients.
Conclusions:
- Accurate differentiation between FGN-MGRS and FGN with incidental MGUS requires improved diagnostic strategies.
- The discovery of DNAJB9 offers a potential diagnostic tool for FGN, reducing reliance on electron microscopy (EM).
- Further research integrating advanced techniques like IF-P, IgG subtyping, VH/VL domain analysis, and DNAJB9 is crucial for understanding FGN and MGRS.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Acute Pyelonephritis II: Diagnostic Studies and Management

